FDA PLAY// LOW FLOAT (46M), 3 CATALYSTS, 500M MCAP, 200M CASH ON HAND, TAKEOVER TARGET BY BIG PHARMA
BLOCKBUSTER DRUG Fidaxomicin, BILLION DOLLAR MARKET CAP POTENTIAL!! TAKEOVER TARGET BY BIG PHARMA!!
Optimer (OPTR) is developing the 1st drug in 25 years to treat C. diff, an infection responsible killing many hospital patients every year. The disease is difficult to treat with current therapy due to high recurrence rate. Fidaxomicin decreases recurrence rate by > 45% vs. standard treatment.